FOLH1 and cancer: Lutathera® and Pluvicto® both target highly cancer-specific targets (somatostatin receptor (SSTR) and PSMA, respectively) but target expression is limited to specific forms of cancer, primarily those of neuroendocrine origin that tend to express SSTR, and prostate cancers expressing PSMA.